Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults

Phase 2

Completed

• Conditions: Meningococcal Meningitis, Serogroup A; Meningococcal Meningitis, Serogroup C; Meningococcal Meningitis, Serogroup Y; Meningococcal Meningitis, Serogroup B; Meningococcal Meningitis, Serogroup W

• Registration Number: NCT00962624
• Lead Sponsor: Prof. Elizabeth Miller

Brief Summary

The study involves the measurement of immune response to vaccination with three doses of a meningococcal B vaccine and a single dose of a meningococcal ACYW conjugate vaccine in healthy adults (Laboratory workers). The study will be completed at the Manchester Medical Microbiology Partnership in the UK and will enrol staff who may be at potential occupational exposure to meningococci. Blood samples will be taken before and after each vaccination and used to determine if the vaccines induce protective responses.

Detailed Description

Laboratory staff at the Manchester Medical Microbiology Partnership may be at potential occupational exposure to meningococci. No licensed vaccine is available against serogroup B meningococci and the available plain polysaccharide serogroup ACYW vaccine is poorly immunogenic. Novartis Vaccines have developed an investigational serogroup B vaccine and a conjugated ACYW vaccine. This study will investigate these vaccines ability to induce a protective response in laboratory staff from the Manchester Medical Microbiology Partnership. Three doses of the meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose will be administered at 0 months. Blood samples will be taken before and after each vaccination and functional antibodies determined.

Study Timeline

• Study First Submitted: 2009-08-19
• Study First Submitted QC: 2009-08-19
• Study First Posted: 2009-08-20
• Study Start: 2010-07
• Primary Completion: 2011-03
• Study Completion: 2012-03
• Status Verified: 2018-09
• Last Update Submitted: 2018-09-17
• Last Update Posted: 2018-09-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• Aged 18-65 years of age
• Who have given written informed consent after the nature of the study has been explained.
• Who work within the Manchester Medical Microbiology Partnership and may be at potential occupational exposure to meningococci.

Exclusion Criteria

• The possibility of pregnancy
• A serious chronic disease including progressive neurological disease or seizure disorder.
• Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
• Have a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component.
• Have received another investigational agent within 90 days or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another investigational trial through the end of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Proportion of subjects attaining putative protective antibody concentrations against meningococci in the serum bactericidal antibody assay	one month following the last vaccination

Trial Locations

Locations (1)

Manchester Medical Microbiology Partnership; 🇬🇧 Manchester, United Kingdom